Henry Schein (HSIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael ...
Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on Henry Schein (HSIC – Research Report) on November 5 and set a price ...
Henry Schein is a Fortune 500 company and one of the global leaders in its industry, providing healthcare solutions, as well as the distribution of medical, dental, and veterinary supplies.
Seeking Alpha on MSN12h
Henry Schein extends gain on report of activist stake, push for board changesHenry Schein (NASDAQ:HSIC) rose 7.4% amid a report that an activist investor has taken a stake and is pushing for the dental ...
Activist investor Ananym Capital Management is urging healthcare products distributor Henry Schein to refresh its board, cut costs, tackle succession planning and consider selling its medical ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.5, a high estimate of $82.00, ...
Henry Schein posts Q3 adjusted EPS of $1.23, topping forecasts, while sales of $3.17 billion fall short. The company revises ...
We have also had multiple successes with customers that have switched to Henry Schein for their merchandise and equipment purchases as a result of our differentiated offering and the excellent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback